Search

Your search keyword '"Akre O"' showing total 320 results
Start Over Author "Akre O"
320 results on '"Akre O"'

3. The impact of the time elapsed between primary treatment and BCR on cancer specific mortality in patients who experienced BCR after primary treatment

Author

Pellegrino, F., primary, Falagario, U.G., additional, Abbadi, A., additional, Björnebo, L., additional, Valdman, A., additional, Carrieri, G., additional, Briganti, A., additional, Montorsi, F., additional, Akre, O., additional, Aly, M., additional, Eklund, M., additional, Nordström, T., additional, Grönberg, H., additional, Lantz, A., additional, and Wiklund, P., additional

Published
2024
Full Text
View/download PDF

4. Time to death and clinical characteristics of patients who died for prostate cancer after robot-assisted radical prostatectomy: 20 years’ report from the EAU Robotic Urology Section (ERUS) scientific working group

Author

Falagario, U.G., primary, Pellegrino, F., additional, Moschovas, M.C., additional, Knipper, S., additional, Martini, A., additional, Akre, O., additional, Egevad, L., additional, Aly, M., additional, Bravi, C.A., additional, Tran, J., additional, Heiniger, Y., additional, Von Kempis, A., additional, Schaffar, R., additional, Carrieri, G., additional, Briganti, A., additional, Montorsi, F., additional, Rochat, C-H., additional, Mottrie, A., additional, Ahlering, T.E., additional, John, H., additional, Patel, V., additional, Graefen, M., additional, and Wiklund, P., additional

Published
2024
Full Text
View/download PDF

5. PSA response after radiotherapy. Is there a definition of PSA persistence after RT?

Author

Falagario, U.G., primary, Pellegrino, F., additional, Abbadi, A., additional, Björnebo, L., additional, Valdman, A., additional, Carrieri, G., additional, Briganti, A., additional, Montorsi, F., additional, Akre, O., additional, Aly, M., additional, Eklund, M., additional, Nordström, T., additional, Grönberg, H., additional, Wiklund, P., additional, and Lantz, A., additional

Published
2024
Full Text
View/download PDF

6. Organised prostate cancer testing in Sweden – results from the first three years of inviting 50-year-old men

Author

Arnsrud Godtman, R., primary, Jiborn, T., additional, Wallström, J., additional, Akre, O., additional, Carlsson, S., additional, Nordström, T., additional, Thimansson, E., additional, Alterbeck, M., additional, Zackrisson, S., additional, Hugosson, J., additional, Bjartell, A., additional, Lantz, A., additional, and Bratt, O., additional

Published
2024
Full Text
View/download PDF

7. Accuracy of the MRI 5-point Likert score to predict extra-prostatic extension and seminal vesicle invasion in patients undergoing radical prostatectomy for prostate cancer and development of a new MRI-based nomogram.

Author

Pellegrino, F., primary, Falagario, U.G., additional, Proietti, F., additional, Brasetti, A., additional, Hagman, A., additional, Briganti, A., additional, Montorsi, F., additional, Carrieri, G., additional, Lantz, A., additional, Akre, O., additional, Aly, M., additional, Egevad, L., additional, Jaderling, F., additional, and Wiklund, P., additional

Published
2024
Full Text
View/download PDF

8. Identify the optimal candidates for adjuvant androgen deprivation therapy among patients with detectable PSA after radical prostatectomy

Author

Pellegrino, F., primary, Falagario, U.G., additional, Knipper, S., additional, Martini, A., additional, Akre, O., additional, Aly, M., additional, Moschovas, M.C., additional, Bravi, C.A., additional, Tran, J., additional, Heiniger, Y., additional, Von Kempis, A., additional, Schaffar, R., additional, Carrieri, G., additional, Briganti, A., additional, Montorsi, F., additional, Rochat, C-H., additional, Mottrie, A., additional, Ahlering, T.E., additional, John, H., additional, Patel, V., additional, Graefen, M., additional, and Wiklund, P., additional

Published
2024
Full Text
View/download PDF

11. The impact of positive surgical margins on long term survival after robot assisted radical prostatectomy: 20 years’ report from the EAU Robotic Urology Section (ERUS) Scientific Working Group

Author

Pellegrino, F., primary, Falagario, U.G., additional, Knipper, S., additional, Martini, A., additional, Akre, O., additional, Egevad, L., additional, Grönberg, H., additional, Moschovas, M.C., additional, Bravi, C.A., additional, Tran, J., additional, Heiniger, Y., additional, Von Kempis, A., additional, Schaffar, R., additional, Briganti, A., additional, Montorsi, F., additional, Rochat, C-H., additional, Mottrie, A., additional, Ahlering, T.E., additional, John, H., additional, Patel, V., additional, Graefen, M., additional, and Wiklund, P., additional

Published
2023
Full Text
View/download PDF

12. Prostate cancer specific and all-cause mortality after robot-assisted radical prostatectomy: 20 years’ report from the EAU Robotic Urology Section (ERUS) Scientific Working Group

Author

Falagario, U.G., primary, Knipper, S., additional, Pellegrino, F., additional, Martini, A., additional, Akre, O., additional, Egevad, L., additional, Grönberg, H., additional, Covas Moschovas, M., additional, Bravi, C.A., additional, Tran, J., additional, Heiniger, Y., additional, Von Kempis, A., additional, Carrieri, G., additional, Schaffar, R., additional, Rochat, C-H., additional, Mottrie, A., additional, Ahlering, T.E., additional, John, H., additional, Patel, V., additional, Graefen, M., additional, and Wiklund, P., additional

Published
2023
Full Text
View/download PDF

23. PE028 - Prostate cancer specific and all-cause mortality after robot-assisted radical prostatectomy: 20 years’ report from the EAU Robotic Urology Section (ERUS) Scientific Working Group

Author

Falagario, U.G., Knipper, S., Pellegrino, F., Martini, A., Akre, O., Egevad, L., Grönberg, H., Covas Moschovas, M., Bravi, C.A., Tran, J., Heiniger, Y., Von Kempis, A., Carrieri, G., Schaffar, R., Rochat, C-H., Mottrie, A., Ahlering, T.E., John, H., Patel, V., Graefen, M., and Wiklund, P.

Published
2023
Full Text
View/download PDF

25. PE020 - The impact of positive surgical margins on long term survival after robot assisted radical prostatectomy: 20 years’ report from the EAU Robotic Urology Section (ERUS) Scientific Working Group

Author

Pellegrino, F., Falagario, U.G., Knipper, S., Martini, A., Akre, O., Egevad, L., Grönberg, H., Moschovas, M.C., Bravi, C.A., Tran, J., Heiniger, Y., Von Kempis, A., Schaffar, R., Briganti, A., Montorsi, F., Rochat, C-H., Mottrie, A., Ahlering, T.E., John, H., Patel, V., Graefen, M., and Wiklund, P.

Published
2023
Full Text
View/download PDF

31. Prognostic utility of the Gleason grading system revisions

Author

Zelic, R., primary, Giunchi, F., additional, Fridfeldt, J., additional, Carlsson, J., additional, Davidsson, S., additional, Lianas, L., additional, Mascia, C., additional, Zugna, D., additional, Molinaro, L., additional, Vincent, P.H., additional, Zanetti, G., additional, Andrén, O., additional, Richiardi, L., additional, Akre, O., additional, Fiorentino, M., additional, and Pettersson, A., additional

Published
2020
Full Text
View/download PDF

32. Residual/recurrent disease and deaths at 6 years after open or robotic-assisted radical prostatectomy in the prospective, controlled trial LAPPRO

Author

Nyberg, M.P., primary, Akre, O., additional, Bock, D., additional, Carlsson, S.V., additional, Carlsson, S., additional, Hugosson, J., additional, Steineck, G., additional, Stranne, J., additional, Tyritzis, S., additional, Wiklund, P., additional, Haglind, E., additional, and Bjartell, A.S., additional

Published
2020
Full Text
View/download PDF

33. Oncologic outcomes of patients with incidental prostate cancer who underwent RARC: a comparison between nerve sparing and non-nerve sparing approach

Author

Chessa, F., primary, Möller, A., additional, Collins, J., additional, Laurin, O., additional, Aly, M., additional, Schiavina, R., additional, Adding, C., additional, Distefano, C., additional, Akre, O., additional, Bertaccini, Alessandro, additional, Hosseini, A., additional, Brunocilla, E., additional, and Wiklund, P., additional

Published
2020
Full Text
View/download PDF

38. Oncologic outcomes of patients with incidental prostate cancer who underwent robot-assisted radical cystectomy: A comparison between nerve sparing and non-nerve sparing approach

Author

Chessa, F., primary, Moller, A., additional, Laurin, O., additional, Adding, C., additional, Aly, M., additional, Collins, J., additional, Luciani, L., additional, Schiavina, R., additional, Brunocilla, E., additional, Akre, O., additional, Hosseini, A., additional, and Wiklund, P., additional

Published
2019
Full Text
View/download PDF

39. SPCG-15 : a prospective randomized study comparing primary radical prostatectomy and primary radiotherapy plus androgen deprivation therapy for locally advanced prostate cancer

Author

Stranne, J., Brasso, K., Brennhovd, B., Johansson, Eva, Jäderling, F., Kouri, M., Lilleby, W., Petersen, P. Meidahl, Mirtti, T., Pettersson, A., Rannikko, A., Thellenberg, C., Akre, O., Stranne, J., Brasso, K., Brennhovd, B., Johansson, Eva, Jäderling, F., Kouri, M., Lilleby, W., Petersen, P. Meidahl, Mirtti, T., Pettersson, A., Rannikko, A., Thellenberg, C., and Akre, O.

Abstract

Objective: To describe study design and procedures for a prospective randomized trial investigating whether radical prostatectomy (RP) ± radiation improves cause-specific survival in comparison with primary radiation treatment (RT) and androgen deprivation treatment (ADT) in patients with locally advanced prostate cancer (LAPC). Materials and methods: SPCG-15 is a prospective, multi-centre, open randomized phase III trial. Patients are randomized to either standard (RT + ADT) or experimental (RP with extended pelvic lymph-node dissection and with addition of adjuvant or salvage RT and/or ADT if deemed necessary) treatment. Each centre follows guidelines regarding the timing and dosing of postoperative RT and adjuvant treatment such as ADT The primary endpoint is cause-specific survival. Secondary endpoints include metastasis-free and overall survival, quality-of-life, functional outcomes and health-services requirements. Each subject will be followed up for a minimum of 10 years. Results: Twenty-three centres in Denmark, Finland, Norway and Sweden, well established in performing RP and RT for prostate cancer participated. Each country’s sites were coordinated by national coordinating investigators and sub-investigators for urology and oncology. Almost 400 men have been randomized of the stipulated 1200, with an increasing rate of accrual. Conclusions: The SPCG-15 trial aims to compare the two curatively intended techniques supplying new knowledge to support future decisions in treatment strategies for patients with LAPC The Scandinavian healthcare context is well suited for performing multi-centre long-term prospective randomized clinical trials. Similar care protocols and a history of entirely tax-funded healthcare facilitate joint trials.

Published
2018
Full Text
View/download PDF

40. SPCG-15:a prospective randomized study comparing primary radical prostatectomy and primary radiotherapy plus androgen deprivation therapy for locally advanced prostate cancer

Author

Stranne, J., Brasso, K., Brennhovd, B., Johansson, E., Jäderling, F., Kouri, M., Lilleby, W., Meidahl Petersen, P., Mirtti, T., Pettersson, A., Rannikko, A., Thellenberg, C., Akre, O., Stranne, J., Brasso, K., Brennhovd, B., Johansson, E., Jäderling, F., Kouri, M., Lilleby, W., Meidahl Petersen, P., Mirtti, T., Pettersson, A., Rannikko, A., Thellenberg, C., and Akre, O.

Abstract

Objective: To describe study design and procedures for a prospective randomized trial investigating whether radical prostatectomy (RP) ± radiation improves cause-specific survival in comparison with primary radiation treatment (RT) and androgen deprivation treatment (ADT) in patients with locally advanced prostate cancer (LAPC). Materials and methods: SPCG-15 is a prospective, multi-centre, open randomized phase III trial. Patients are randomized to either standard (RT + ADT) or experimental (RP with extended pelvic lymph-node dissection and with addition of adjuvant or salvage RT and/or ADT if deemed necessary) treatment. Each centre follows guidelines regarding the timing and dosing of postoperative RT and adjuvant treatment such as ADT The primary endpoint is cause-specific survival. Secondary endpoints include metastasis-free and overall survival, quality-of-life, functional outcomes and health-services requirements. Each subject will be followed up for a minimum of 10 years. Results: Twenty-three centres in Denmark, Finland, Norway and Sweden, well established in performing RP and RT for prostate cancer participated. Each country’s sites were coordinated by national coordinating investigators and sub-investigators for urology and oncology. Almost 400 men have been randomized of the stipulated 1200, with an increasing rate of accrual. Conclusions: The SPCG-15 trial aims to compare the two curatively intended techniques supplying new knowledge to support future decisions in treatment strategies for patients with LAPC The Scandinavian healthcare context is well suited for performing multi-centre long-term prospective randomized clinical trials. Similar care protocols and a history of entirely tax-funded healthcare facilitate joint trials.

Published
2018

41. SPCG-15: a prospective randomized study comparing primary radical prostatectomy and primary radiotherapy plus androgen deprivation therapy for locally advanced prostate cancer

Author

Stranne, J., primary, Brasso, K., additional, Brennhovd, B., additional, Johansson, E., additional, Jäderling, F., additional, Kouri, M., additional, Lilleby, W., additional, Meidahl Petersen, P., additional, Mirtti, T., additional, Pettersson, A., additional, Rannikko, A., additional, Thellenberg, C., additional, and Akre, O., additional

Published
2018
Full Text
View/download PDF

43. Oncologic outcomes of robot assisted vs open radical cystectomy: Results from a high-volume referral centre

Author

Chessa, F., primary, Möller, A., additional, Schiavina, R., additional, Borghesi, M., additional, Laurin, O., additional, Dababneh, H., additional, Aly, M., additional, Adding, C., additional, Miyakawa, A., additional, Pultrone, C., additional, Akre, O., additional, Hosseini, A., additional, Brunocilla, E., additional, and Wiklund, P., additional

Published
2018
Full Text
View/download PDF

44. Soluble urokinase plasminogen activator receptor as a prognostic marker in men participating in prostate cancer screening

Author

Kjellman, A, Akre, O, Gustafsson, O, Høyer-Hansen, G, Lilja, H, Norming, U, Piironen, T, and Törnblom, M

Abstract

BACKGROUND: The urokinase plasminogen activator (uPA) system is involved in tissue remodelling processes and is up-regulated in many types of malignancies. We investigated whether serum levels of different forms of soluble uPA receptor (suPAR) are associated with survival and in particular with prostate cancer and cardiovascular disease mortality. METHODS: Using time-resolved fluorescence immunoassays, we measured intact suPAR [suPAR(I-III)] and intact plus cleaved suPAR [suPAR(I-III) + suPAR(II-III)] and thus calculated the amount of suPAR(II-III) in serum samples from 375 men participating in a prostate cancer screening trial. A total of 312 men were free of prostate cancer and 63 men had prostate cancer diagnosed at the time of screening. The cohort was followed for 15 years. We assessed survival using Kaplan-Meier estimation and Cox proportional hazards regression. RESULTS: The mean age at blood sampling was 64 years. In total, 152 men died during follow-up. SuPAR(I-III) and suPAR(II-III) were significantly positively associated with mortality (P = 0.001 and P < 0.0001, respectively). In a Cox regression model adjusting for age and prostate cancer status, an increase in suPAR(I-III) and suPAR(II-III) by 1-unit (ln-scale) was associated with a hazard ratio (HR) of 2.26 [95% confidence interval (CI) 1.17-4.35] and 2.53 (95% CI 1.56-4.10), respectively. There was a trend towards an increased risk of death from prostate cancer in screening-detected prostate cancer patients with increased values of either suPAR form. However, this difference was not significant and the association disappeared after adjusting for age, tumour stage, tumour grade and prostate-specific antigen. Being in the highest quartile of any of the suPAR forms was associated with a highly significant increased risk of cardiovascular death, with HR adjusted for age of 3.27 (95% CI 1.38-7.73) for suPAR(I-III) quartile 4 versus quartile 1. Conclusions. High concentrations of serum suPAR(I-III) and suPAR(II-III) were associated with poor overall survival. The association was particularly strong for death from cardiovascular disease. No similar association was found for prostate cancer after adjustment for other prognostic factors.

Published
2016

45. The impact of length and location of positive margins in predicting biochemical recurrence after robot-assisted radical prostatectomy with a minimum follow-up of 5 years

Author

Sooriakumaran, P, Ploumidis, A, Nyberg, T, Olsson, M, Akre, O, Haendler, L, Egevad, L, Nilsson, A, Carlsson, S, Jonsson, M, Adding, C, Hosseini, A, Steineck, G, and Wiklund, P

Abstract

OBJECTIVE: To evaluate the role of positive surgical margin (PSM) size/focality and location in relation to risk of biochemical recurrence (BCR) after robot-assisted radical prostatectomy (RARP). PATIENTS AND METHODS: Clinicopathological data were collected from 904 patients who underwent RARP at a single European institution from 2002 to 2006. PSM status after RARP was defined as cancer cells at the inked margin, and was stratified by size/focality and location. The outcome variable was BCR, defined as a postoperative PSA level of ≥0.2 ng/mL. We modelled clinicopathological covariates including PSM size/focality and location using Cox proportional hazards regression. In subgroup analyses, we assessed the effect of PSM size and location at different pathological stages and grades of disease. RESULTS: Compared with negative SM, a PSM of >3 mm/multifocal was associated with an increased risk of BCR in the entire cohort (hazard ratio [HR] 2.84, 95% confidence interval 1.76-4.59), while unifocal PSMs of ≤3 mm were not significantly associated with BCR. In subgroup analyses, the negative impact of >3 mm/multifocal PSM appeared greatest in those with lower postoperative stage and grade of disease. The prognostic role of PSM location was unconfirmed, although data indicated that posterolateral PSMs may be of lower significance in RARP patients. The study is limited by lack of central pathology review, and lack of statistical adjustment for tumour volume, lymph node status, and surgeon volume. CONCLUSION: We found that men with >3 mm/multifocal PSMs have a higher risk of BCR than those with unifocal PSMs of ≤3 mm or negative SMs, especially if they have lower risk disease. Posterolateral margins may be of little significance in a RARP population.

Published
2016

49. Testicular cancer incidence in eight northern European countries: secular and recent trends

Author

Richiardi, L, Bellocco, R, Adami, H, Torrång, A, Barlow, L, Hakulinen, T, Rahu, M, Stengrevics, A, Storm, H, Tretli, S, Kurtinaitis, J, Tyczynski, J, Akre, O, Akre, O., BELLOCCO, RINO, Richiardi, L, Bellocco, R, Adami, H, Torrång, A, Barlow, L, Hakulinen, T, Rahu, M, Stengrevics, A, Storm, H, Tretli, S, Kurtinaitis, J, Tyczynski, J, Akre, O, Akre, O., and BELLOCCO, RINO

Abstract

Striking geographic variation and marked increasing secular trends characterize the incidence of testicular cancer. However, it is not known whether these patterns have attenuated in recent years and whether they are similar for seminomas and nonseminomas, the two main histologic groups of testicular cancer.

Published
2004

50. Original articleSelective intraoperative cholangiography and risk of bile ductinjury during cholecystectomy

Author

Törnqvist, B, Strömberg, C, Akre, O, Enochsson, Lars, Nilsson, M, Törnqvist, B, Strömberg, C, Akre, O, Enochsson, Lars, and Nilsson, M

Abstract

BACKGROUND: Whether intraoperative cholangiography can prevent iatrogenic bile duct injury during cholecystectomy remains controversial. METHODS: Data from the national Swedish Registry for Gallstone Surgery, GallRiks (May 2005 to December 2010), were analysed for evidence of iatrogenic bile duct injury during cholecystectomy. Patient- and procedure-related risk factors for bile duct injury with a focus on the rate of intended intraoperative cholangiography were analysed using multivariable logistic regression. RESULTS: A total of 51 041 cholecystectomies and 747 bile duct injuries (1·5 per cent) were identified; 9008 patients (17·6 per cent) were diagnosed with acute cholecystitis. No preventive effect of intraoperative cholangiography was seen in uncomplicated gallstone disease (odds ratio (OR) 0·97, 95 per cent c.i. 0·74 to 1·25). Operating in the presence (OR 1·23, 1·03 to 1·47) or a history (OR 1·34, 1·10 to 1·64) of acute cholecystitis, and open surgery (OR 1·56, 1·26 to 1·94), were identified as significant risk factors for bile duct injury. The intention to perform intraoperative cholangiography was associated with a reduced risk of bile duct injury in patients with concurrent (OR 0·44, 0·30 to 0·63) or a history of (OR 0·59, 0·35 to 1·00) acute cholecystitis. CONCLUSION: Any proposed protective effect of intraoperative cholangiography was restricted to patients with (or a history of) acute cholecystitis.

Published
2015
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results